BridgeBio Pharma Total Current Liabilities 2018-2024 | BBIO

BridgeBio Pharma total current liabilities for the quarter ending December 31, 2024 were $0.154B, a 7.34% increase year-over-year.

  • BridgeBio Pharma total current liabilities for 2024 were $0.154B, a 7.34% increase from 2023.
  • BridgeBio Pharma total current liabilities for 2023 were $0.144B, a 18.46% increase from 2022.
  • BridgeBio Pharma total current liabilities for 2022 were $0.121B, a 10.1% decline from 2021.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$15.5B
Dr Reddy's Laboratories (RDY)$11.4B
Bausch Health Cos (BHC)$1.9B
Supernus Pharmaceuticals (SUPN)$1.7B
Amphastar Pharmaceuticals (AMPH)$1.1B
Personalis (PSNL)$282M
Taysha Gene Therapies (TSHA)$254M
Assembly Biosciences (ASMB)$75M
Sol-Gel Technologies (SLGL)$15M
Evoke Pharma (EVOK)$3M
Teligent (TLGT)$0M